VIVUS, Inc. news

   Watch this stock
Showing stories 1 - 4 of about 4   

Articles published

VVUS 1.06 -0.03 (-2.75%)
price chart
FDA Decisions: Biotech Companies Waiting For FDA Approval
When a biotech company is developing a drug, the process can take ten years or more. There are many steps in the development process, including initial design, testing, changes in design, more testing, and application for federal approval.
Arena Pharma's 5-Year Revenue Forecast
I just posted a research report video on YouTube that includes my five-year revenue forecast for Arena Pharmaceuticals (NASDAQ:ARNA).
Qnexa Diet Pill: Making A Weight-Loss Drug That Doesn't Sicken You Is ...
Research presented to the FDA by Vivus, the company developing Qnexa, shows why the drug has a shot at approval: patients in a study lost an average of about 10 percent of their body weight in a year.
Time For Credit Suisse To Open TVIX Books
Massachusetts's securities regulator said it is looking into the VelocityShares 2x Long VIX Short Term Exchange note (TVIX), managed by Credit Suisse.